[ARS] Marker Therapeutics, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

03/20/2026 - 04:07 PM

ARS - Marker Therapeutics, Inc.

ARS Filing - Marker Therapeutics, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Marker Therapeutics, Inc. (MRKR)

Acceptance Date: 2026-03-20T16:07:05.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Marker Therapeut

NASDAQ:MRKR

View MRKR Stock Overview →

MRKR Rankings

#6079 Ranked by Market Cap

N/A Ranked by Dividends

MRKR Latest News

Mar 18, 2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Feb 18, 2026

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 26, 2026

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Jan 5, 2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Nov 14, 2025

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

MRKR Latest SEC Filings

Mar 20, 2026

[DEF 14A] Marker Therapeutics, Inc. Definitive Proxy Statement

Mar 18, 2026

[8-K] Marker Therapeutics, Inc. Reports Material Event

Mar 18, 2026

[10-K] Marker Therapeutics, Inc. Files Annual Report

Mar 10, 2026

[PRE 14A] Marker Therapeutics, Inc. Preliminary Proxy Statement

Feb 9, 2026

[8-K] Marker Therapeutics, Inc. Reports Material Event

MRKR Stock Data

Market Cap 22.34M

Float 15.76M

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City HOUSTON